| Literature DB >> 14518415 |
Akimasa Matsushita1, Kazuhiro Hanazaki, Terumasa Noike, Kan Nakagawa, Ryosuke Misawa, Takenari Nakata, Kazuhiko Nomura, Akira Kobayashi, Shiro Miwa, Shinichi Miyagawa, Seiji Kawasaki.
Abstract
UFT is an anti-cancer drug which combines uracil with tegafur at a mole rate of 1:4, and shows a high anti-tumor effect by raising the 5-FU level in a tumor. A 55-year-old man with hypochondriac pain was admitted to Shinshu University Hospital. The preoperative diagnosis was giant hepatocellular carcinoma (HCC) of the right hepatic anterior region, and extended anterior segmentectomy of the liver was performed. Three months later, serum alpha-fetoprotein (AFP) and PIVKA-II were elevated markedly, and computed tomography (CT) and magnetic resonance imaging (MRI) revealed a recurrence in the remnant liver and multiple lung metastasis. Chemotherapy with oral UFT (300 mg/day) administration alone was started for the unresectable HCC. Three months later, CT and MRI showed complete disappearance of the recurrent HCC and multiple lung metastasis. Also, the titers of AFP and PIVKA-II were reduced to normal levels. This case suggests that oral UFT administration is a safe and effective therapy for postoperative HCC, even with lung metastasis.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14518415
Source DB: PubMed Journal: Gan To Kagaku Ryoho ISSN: 0385-0684